New Hope for Macular Telangiectasia Type 2: FDA Approves ENCELTO, Neurotech's Innovative Cell Therapy

New Hope for Macular Telangiectasia Type 2: FDA Approves ENCELTO, Neurotech's Innovative Cell Therapy

The inherited retinal disease (IRD) community is celebrating a significant development with the U.S. Food and Drug Administration (FDA) approval of ENCELTO (revakinagene taroretcel-lwey), a novel cell therapy from Neurotech Pharmaceuticals Inc. This approval marks a crucial step forward, offering the first and only FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel), a rare neurodegenerative retinal disease that causes progressive and irreversible vision loss. This news brings renewed hope to patients and families affected by this challenging condition.

Neurotech Pharmaceuticals Inc. announced the FDA approval for ENCELTO in March 2025. The Rhode Island-based biotech company's treatment addresses MacTel, a condition where blood vessels in the macula become dilated and leak, leading to central vision loss. ENCELTO is designed to slow the progression of this disease.

Key facts about ENCELTO and its approval include:
* First-of-its-kind Treatment: ENCELTO is the first and only FDA-approved treatment specifically for MacTel.
* Mechanism of Action: The therapy involves a small, semi-permeable capsule containing genetically modified retinal cells. This capsule is surgically implanted into the eye and continuously delivers therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina. This protein helps photoreceptors survive longer, thereby slowing the disease progression.
* Surgical Procedure: The implantation procedure is described as straightforward and takes approximately 10 minutes. The technology behind ENCELTO took over 20 years to develop, and once implanted, it provides sustained drug delivery, potentially for many years.
* Clinical Efficacy: The approval was based on results from two Phase 3 trials, which demonstrated that ENCELTO significantly slowed the loss of macular photoreceptors in MacTel patients over 24 months. In these studies, the cell therapy reduced the rate of progression of MacTel compared to a sham procedure by 56.4% and 29.2%.
* Availability: Neurotech expects ENCELTO to be available to U.S. patients starting in June 2025.

For patients and families living with MacTel, this approval represents a monumental step forward. Previously, there were no FDA-approved treatments available to address the progressive vision loss associated with the disease. The sustained delivery mechanism of ENCELTO, requiring a single surgical procedure rather than frequent injections, could significantly improve the quality of life for those affected. Neurotech's CEO, Richard Small, highlighted this as an